Request Demo
Last update 01 Oct 2025
Ezetimibe/Pitavastatin Calcium
Last update 01 Oct 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Pitavastatin Calcium Hydrate/Ezetimibe, 依折麦布/匹伐他汀钙, AD-2284 + [6] |
Target |
Action inhibitors |
Mechanism CETP inhibitors(Cholesteryl ester transfer protein inhibitors), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (28 Jul 2021), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC25H24CaFNO4 |
InChIKeyAMUDYCAFPCQTAZ-NRFPMOEYSA-N |
CAS Registry147526-32-7 |
View All Structures (2)
Related
5
Clinical Trials associated with Ezetimibe/Pitavastatin CalciumNCT06858865
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 in Healthy Adult Volunteers
NCT06884098
An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers
CTR20222390
依折麦布匹伐他汀钙片的生物等效性试验
[Translation] Bioequivalence study of ezetimibe and pitavastatin calcium tablets
100 Clinical Results associated with Ezetimibe/Pitavastatin Calcium
Login to view more data
100 Translational Medicine associated with Ezetimibe/Pitavastatin Calcium
Login to view more data
100 Patents (Medical) associated with Ezetimibe/Pitavastatin Calcium
Login to view more data
100 Deals associated with Ezetimibe/Pitavastatin Calcium
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hypercholesterolemia | Japan | 26 Sep 2022 | |
| Hyperlipoproteinemia Type II | Japan | 26 Sep 2022 | |
| Primary hypercholesterolemia | South Korea | 28 Jul 2021 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Homozygous familial hypercholesterolemia | Phase 1 | China | 20 Sep 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 109 | K-924 LD: 2 mg/10 mg | anmpmgekvy(fvzrxghydn) = rjmxcpcuvy avlpysqala (ghmqecnkyg ) | Positive | 01 Mar 2024 | ||
K-924 HD: 4 mg/10 mg | anmpmgekvy(fvzrxghydn) = uhiufrrzoe avlpysqala (ghmqecnkyg ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free